Actively Recruiting

Phase 3
Age: 18Years +
All Genders
NCT07495852

Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

Led by Glaukos Corporation · Updated on 2026-03-30

510

Participants Needed

1

Research Sites

314 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

CONDITIONS

Official Title

Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosis of Ocular Hypertension or Open-Angle Glaucoma in the study eye
Not Eligible

You will not qualify if you...

  • Prior incisional glaucoma surgery in the study eye
  • Prior argon laser trabeculoplasty (ALT) in the study eye
  • Prior minimally invasive glaucoma (MIGS) surgery in the study eye

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Glaukos Investigative Site

Dothan, Alabama, United States, 36301

Actively Recruiting

Loading map...

Research Team

S

Study Director

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

6

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here